NEW YORK (GenomeWeb News) — Transgenomic today said it will analyze cancer pathway genes for OSI Pharmaceuticals using a high-throughput methodology it developed for characterizing gene variants in malignant tumors.
 
Transgenomic said its high-throughput scanning offers forward and reverse Sanger sequencing and variant annotation to detect the mutations, and that it will be used to help OSI in its cancer drug-development programs.
 
Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.